Indole Analogs as Novel Appetite Suppressants

Information

  • Research Project
  • 7492306
  • ApplicationId
    7492306
  • Core Project Number
    R44DK065322
  • Full Project Number
    5R44DK065322-04
  • Serial Number
    65322
  • FOA Number
    PA-06-20
  • Sub Project Id
  • Project Start Date
    9/1/2003 - 21 years ago
  • Project End Date
    8/31/2010 - 14 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L.
  • Budget Start Date
    9/1/2008 - 16 years ago
  • Budget End Date
    8/31/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    4
  • Suffix
  • Award Notice Date
    8/20/2008 - 16 years ago
Organizations

Indole Analogs as Novel Appetite Suppressants

[unreadable] DESCRIPTION (provided by applicant): Obesity affects millions of people in the U.S. and worldwide, and this disease has enormous health and economic consequences for our society. Existing treatments show limited efficacy, can possess troubling side effects, and often require long-term therapy. Discovery of a new treatment for obesity would have a very considerable scientific and commercial value. One approach to pharmacotherapy for appetite suppression is the development of 5-HT2C receptor agonists, which was the focus of our Phase One work. In Phase Two, we propose to optimize and further develop these leads through a Structure-Activity Relationship (SAR) program of synthesis and biological evaluation. From this project we specifically aim to discover one or more indole analogs showing efficacy in our animal model for appetite suppression that is equal to or better than approved medications. Such leads will also display favorable drug-like properties. The long-term goal of this project is to discover a new, improved pharmaceutical agent for treatment of obesity that can be licensed and developed for ultimate market approval. 7. Project Narrative Obesity is a serious health problem in the Unites States, and the existing drugs to help people lose weight are often not effective and have side effects. We are carrying out research to discover and develop a new drug for obesity. If we are successful, doctors will have another option to help obese people with their weight problem. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    394714
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:394714\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ORGANIX, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01801
  • Organization District
    UNITED STATES